Compare TSM & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSM | AZN |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | Taiwan | United Kingdom |
| Employees | 83825 | 96100 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7T | 316.4B |
| IPO Year | N/A | N/A |
| Metric | TSM | AZN |
|---|---|---|
| Price | $436.62 | $181.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $387.14 | N/A |
| AVG Volume (30 Days) | ★ 11.7M | 1.9M |
| Earning Date | 04-16-2026 | 04-29-2026 |
| Dividend Yield | 0.67% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.52 | $10.34 |
| Revenue Next Year | $25.10 | $6.43 |
| P/E Ratio | $171.71 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $221.18 | $68.62 |
| 52 Week High | $476.80 | $212.71 |
| Indicator | TSM | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 48.19 |
| Support Level | $395.29 | $174.60 |
| Resistance Level | $450.16 | $191.50 |
| Average True Range (ATR) | 16.41 | 3.02 |
| MACD | 1.34 | -0.03 |
| Stochastic Oscillator | 45.66 | 54.11 |
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with about 70% market share in 2025. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public in Taiwan in 1994 and as an ADR in the US in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious base of customers, including Apple, AMD, and Nvidia, that look to apply its cutting-edge process technologies to their semiconductor designs. TSMC employs more than 83,000 people.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.